v3.26.1
Other Payables
 6 Months Ended
Jun. 30, 2026
Trade and other payables [abstract]  
Other Payables
Note 10 - Other Payables
June 30,December 31,
20262025
Liabilities related to collaboration agreements$98 $79 
Staff cost liabilities106 171 
Accounts payable116 145 
Accrued R&D340 410 
Accrued interest on borrowings7 — 
Other liabilities145 269 
Total$812 $1,074 
Non-current other payables$5 $5 
Current other payables807 1,069 
Total$812 $1,074 
The $262 million decrease in other payables was primarily attributable to higher R&D accruals recorded at year-end 2025 related to accrued termination costs associated with the discontinuance of the acasunlimab and other programs during the fourth quarter of 2025, accrued compensation and bonuses and accrued withholding tax on Merus related option payments paid in the first six months of 2026.
Refer to Note 3.8 in the Annual Report for further details regarding Other payables.